The RAD51C gene encodes a protein crucial for DNA repair. Variants in this gene that stop the protein from working are known to increase the risk of breast and ovarian cancers and rarely, ...

Myriad Genetics ( MYGN ), in order to further expand its product portfolio, obtained rights to the RAD51C gene. Studies have shown that mutations in.

The gene RAD51C is a “cancer protection” gene that encodes a protein crucial for DNA repair. Variants in this gene that stop the protein from working are known to increase the risk of breast ...

The current agreement grants Myriad an exclusive, worldwide license, with co-exclusivity in Germany, to provide commercial testing for RAD51C.

The RAD51C gene encodes a protein crucial for DNA repair. Variants in this gene that stop the protein from working are known to increase the risk of breast and ovarian cancers and rarely, ...

The RAD51C gene encodes a protein crucial for DNA repair. Variants in this gene that stop the protein from working are known to increase the risk of breast and ovarian cancers and rarely, ...

RAD51C has been found to increase the risk of getting these cancers. Myriad Genetics obtained an exclusive license to intellectual property covering the analysis of the RAD51C gene, a risk marker ...

Despite a high prevalence of deleterious missense variants, most studies of RAD51C ovarian cancer susceptibility gene only provide in silico pathogenicity predictions of missense changes. We ...

Variants in BARD1, RAD51C, and RAD51D were associated with moderate risk for estrogen receptor (ER)-negative breast cancer and triple-negative breast cancer, ...

Myriad Genetics, Inc. announced it has obtained an exclusive license to intellectual property covering the analysis of the RAD51C gene for risk of hereditary breast and ovarian cancer. In several ...